Vor Bio, RemeGen succeed in trial for telitacicept in China
Source: SeekingAlpha
2025-08-13 09:49:21 ET
More on Vor Biopharma
- Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants
- Vor Bio appoints Sandy Mahatme as CFO
- Vor Bio surges after private placement, licensing deal
- Seeking Alpha’s Quant Rating on Vor Biopharma
- Historical earnings data for Vor Biopharma
Read the full article on Seeking Alpha
For further details see:
Vor Bio, RemeGen succeed in trial for telitacicept in China
Remegen Co Ltd Reg Shs
NASDAQ: REGMF
REGMF Trading
0.0% G/L:
$10 Last:
1,500 Volume:
$10 Open:
